ADHD Med Buyers Can't Yet Appeal Class Cert. Denial

Law360 (September 11, 2020, 7:50 PM EDT) -- A First Circuit panel has denied a bid by consumers to immediately appeal a Massachusetts federal court's refusal to certify their class in an antitrust suit alleging Shire and Actavis delayed alternatives for Intuniv, a medication for attention deficit hyperactivity disorder.

The circuit court issued a brief order Thursday rejecting a petition from the indirect purchasers that asked for interlocutory review of an August 2019 ruling by U.S. District Judge Allison D. Burroughs that denied their class certification motion.

"Having reviewed the parties' papers and relevant portions of the record, we conclude that the requirements for interlocutory review of class certification...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!